GlassScriptPhysician profile
Jon Steven Yamaguchi
NPI 1720006810
$17,967.37
in general payments reported to CMS, 2019-2025
19 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,116 · 2020: $5,848 · 2021: $3,159 · 2022: $75.51 · 2023: $154 · 2024: $1,512 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153 · Travel and Lodging: $606 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.47 |
| Travel and Lodging | $606.20 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,773.19 | 2019-2025 | |
| Allergan, INC. | $1,709.06 | 2019-2020 | |
| Nuvasive, INC. | $1,137.66 | 2019-2023 | Xlif |
| Janssen Biotech, INC. | $617.47 | 2025 | Tremfya |
| Stryker Corporation | $565.14 | 2020 | |
| Ethicon US, LLC | $331.82 | 2019-2025 | Harmonic, Ligamax, Echelon; Endopath |
| Davol INC. | $169.67 | 2020-2025 | Phasix Mesh |
| Medacta USA, INC. | $144.03 | 2024 | |
| Smith+Nephew, INC. | $127.96 | 2020 | |
| Covidien LP | $92.31 | 2019 | |
| Conmed Corporation | $89.53 | 2019 | |
| W. L. Gore & Associates, INC. | $38.74 | 2022-2023 | Gore Synecor Biomaterial |
| Solventum Corporation | $37.45 | 2024-2025 | V.A.C. Veraflo, Prevena, V.A.C. Dermatac |
| Abbvie INC. | $34.07 | 2023 | Dalvance |
| Regeneron Healthcare Solutions, INC. | $30.26 | 2025 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $23.58 | 2025 | Livmarli |
| Novo Nordisk INC | $17.56 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.09 | 2022 | |
| Zimmer Biomet Holdings, INC. | $13.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Yamaguchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.